Design and optimization of gastro-retentive microballoons for enhanced bioavailability of cinnarizine

Drug Delivery and Translational Research
Hussein O AmmarAlaa H Salama

Abstract

This study is focused on the design of gastro-retentive drug delivery system composed of hollow microspheres (microballoons) for the sustained delivery of cinnarizine (CIN). The microballoons (MBs) were prepared by the emulsion solvent diffusion method using cellulose acetate butyrate (CAB) as the hosting polymer and absolute ethanol (ETH) and dichloromethane (DCM) as solvents. A 3(3) full factorial experimental design was adopted to study the effect of different variables and to find an optimum formula with desired properties. Prepared microballoons showed high drug loading capacities and controlled release behaviour. The optimum formulation was chosen on the basis of achieving maximum values for both drug loading capacity and release efficiency as well as having suitable size. The optimized MB (MB-F21) was composed of 200 mg CIN and 400 mg CAB with a DCM/ETH ratio of 2:1. Scanning electron microscopy for the optimum formulation showed a spherical outline with internal porous structure. An in vivo study using human volunteers was performed by determination of CIN concentration in the plasma using the liquid chromatography-mass spectrometry (LC-MS) method. Results proved the superiority of the designed formulation over the mark...Continue Reading

References

Feb 1, 1992·Journal of Pharmaceutical Sciences·Y KawashimaY Itoh
Jan 1, 1993·The Journal of Pharmacy and Pharmacology·B C ThanooA Jayakrishnan
Aug 10, 2000·Drugs·L J Scott, C M Perry
Aug 10, 2001·Drug Metabolism Reviews·K S SoppimathT M Aminabhavi
Jun 5, 2002·Journal of Clinical Pharmacology·Marilyn N Martinez, Gordon L Amidon
May 20, 2003·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Yasunori SatoHiromitsu Yamamoto
Feb 19, 2004·Archives of Pharmacal Research·Yoon Yeo, Kinam Park
Mar 17, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Yasunori SatoHiromitsu Yamamoto
Sep 29, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Yaw-Bin HuangKozo Takayama
Aug 13, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sunil K JainG P Agrawal
Aug 16, 2005·International Journal of Pharmaceutics·Thorsteinn LoftssonMár Másson
Apr 19, 2006·Headache·Mansooreh ToghaParvin Tajik
Apr 26, 2006·Pediatrics·Dan TurnerYedidia Bentur
Dec 30, 2006·International Journal of Pharmaceutics·Yong-Dan TangLi-Wei Wang
May 9, 2007·International Journal of Pharmaceutics·Pushp R NepalHoo-Kyun Choi
May 10, 2008·Journal of Microencapsulation·V S MastiholimathA R Kulkarni
May 15, 2009·International Journal of Pharmaceutics·Li-Ching ChangTong-Rong Tsai
Sep 23, 2009·International Journal of Pharmaceutics·Shuai ShiXing Tang
Mar 11, 2010·International Journal of Pharmaceutics·Emad B BasaliousShaimaa M Badr-Eldin
Sep 29, 2011·Drug Development and Industrial Pharmacy·Rabab KamelGina El-Feky
Aug 21, 2012·International Journal of Biological Macromolecules·Aashima HoodaPermender Rathee
Aug 21, 2013·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Mahmoud M AhmedMohamed A Ibrahim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.